SBIO.L vs. EQGB.L
SBIO.L (Invesco Nasdaq Biotech UCITS ETF) and EQGB.L (Invesco EQQQ Nasdaq-100 UCITS ETF GBP Hdg Acc) are both exchange-traded funds - SBIO.L is a Health & Biotech Equities fund tracking the NASDAQ Biotechnology TR USD, while EQGB.L is a Nasdaq-100 fund tracking the NASDAQ-100 Index. Both are passively managed. Over the past 5 years, SBIO.L returned 4.66%/yr vs 15.13%/yr for EQGB.L. A 0.57 correlation means they provide meaningful diversification when combined. SBIO.L charges 0.40%/yr vs 0.35%/yr for EQGB.L.
Performance
SBIO.L vs. EQGB.L - Performance Comparison
Loading charts...
Different Trading Currencies
SBIO.L is traded in USD, while EQGB.L is traded in GBp. To make them comparable, the EQGB.L values have been converted to USD using the latest available exchange rates.
Returns By Period
In the year-to-date period, SBIO.L achieves a 4.34% return, which is significantly lower than EQGB.L's 18.57% return.
SBIO.L
- 1D
- 3.10%
- 1M
- -0.64%
- YTD
- 4.34%
- 6M
- 3.70%
- 1Y
- 41.44%
- 3Y*
- 12.99%
- 5Y*
- 4.66%
- 10Y*
- 7.49%
EQGB.L
- 1D
- -0.66%
- 1M
- 7.50%
- YTD
- 18.57%
- 6M
- 19.28%
- 1Y
- 37.80%
- 3Y*
- 30.52%
- 5Y*
- 15.13%
- 10Y*
- —
SBIO.L vs. EQGB.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SBIO.L Invesco Nasdaq Biotech UCITS ETF | 4.34% | 32.89% | -2.00% | 6.14% | -11.85% | -0.49% | 27.35% | 25.54% | -11.34% | -3.53% |
EQGB.L Invesco EQQQ Nasdaq-100 UCITS ETF GBP Hdg Acc | 18.58% | 28.61% | 24.02% | 62.04% | -42.01% | 26.53% | 49.89% | 40.34% | -8.11% | 7.88% |
Correlation
The correlation between SBIO.L and EQGB.L is 0.37, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.37 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.44 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.52 |
Correlation (All Time) Calculated using the full available price history since Oct 19, 2017 | 0.57 |
Over the past year, the correlation between SBIO.L and EQGB.L has dropped to 0.37 - well below their long-term average of 0.57, suggesting their price drivers have been diverging.
SBIO.L vs. EQGB.L - Sectors Allocation Comparison
Sectors
SBIO.L
EQGB.L
Healthcare
Basic Materials
-
Communication Services
-
Consumer Cyclical
-
Consumer Defensive
-
Energy
-
Financial Services
-
Industrials
-
Real Estate
-
Technology
-
Utilities
-
Healthcare
SBIO.L
EQGB.L
Basic Materials
SBIO.L
-
EQGB.L
Communication Services
SBIO.L
-
EQGB.L
Consumer Cyclical
SBIO.L
-
EQGB.L
Consumer Defensive
SBIO.L
-
EQGB.L
Energy
SBIO.L
-
EQGB.L
Financial Services
SBIO.L
-
EQGB.L
Industrials
SBIO.L
-
EQGB.L
Real Estate
SBIO.L
-
EQGB.L
Technology
SBIO.L
-
EQGB.L
Utilities
SBIO.L
-
EQGB.L
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SBIO.L vs. EQGB.L — Risk / Return Rank
SBIO.L
EQGB.L
SBIO.L vs. EQGB.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Invesco Nasdaq Biotech UCITS ETF (SBIO.L) and Invesco EQQQ Nasdaq-100 UCITS ETF GBP Hdg Acc (EQGB.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| SBIO.L | EQGB.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.05 | ||
| Sortino ratioReturn per unit of downside risk | +0.09 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.34 | 0.00 |
| Calmar ratioReturn relative to maximum drawdown | 5.38 | 2.52 | +2.87 |
| Martin ratioReturn relative to average drawdown | 16.56 | 9.34 | +7.21 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| SBIO.L | EQGB.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.09 | 2.05 | +0.05 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.22 | 0.61 | -0.39 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.34 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.27 | 0.79 | -0.52 |
Drawdowns
SBIO.L vs. EQGB.L - Drawdown Comparison
The maximum SBIO.L drawdown since its inception was -39.44%, smaller than the maximum EQGB.L drawdown of -47.56%. Use the drawdown chart below to compare losses from any high point for SBIO.L and EQGB.L.
Loading charts...
Drawdown Indicators
| SBIO.L | EQGB.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -39.44% | -47.56% | +8.12% |
Max Drawdown (1Y)Largest decline over 1 year | -7.64% | -14.96% | +7.32% |
Max Drawdown (3Y)Largest decline over 3 years | -26.88% | -22.21% | -4.67% |
Max Drawdown (5Y)Largest decline over 5 years | -38.33% | -47.56% | +9.23% |
Max Drawdown (10Y)Largest decline over 10 years | -38.33% | — | — |
Current DrawdownCurrent decline from peak | -2.84% | -1.12% | -1.72% |
Average DrawdownAverage peak-to-trough decline | -16.83% | -9.54% | -7.29% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.49% | 4.03% | -1.54% |
Volatility
SBIO.L vs. EQGB.L - Volatility Comparison
Invesco Nasdaq Biotech UCITS ETF (SBIO.L) has a higher volatility of 6.55% compared to Invesco EQQQ Nasdaq-100 UCITS ETF GBP Hdg Acc (EQGB.L) at 5.53%. This indicates that SBIO.L's price experiences larger fluctuations and is considered to be riskier than EQGB.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SBIO.L | EQGB.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.55% | 5.53% | +1.02% |
Volatility (6M)Calculated over the trailing 6-month period | 15.27% | 13.97% | +1.30% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.67% | 18.40% | +1.27% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.21% | 24.75% | -3.54% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.23% | 24.79% | -2.56% |
SBIO.L vs. EQGB.L - Expense Ratio Comparison
SBIO.L has a 0.40% expense ratio, which is higher than EQGB.L's 0.35% expense ratio.
Dividends
SBIO.L vs. EQGB.L - Dividend Comparison
Neither SBIO.L nor EQGB.L has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
EQGB.L Invesco EQQQ Nasdaq-100 UCITS ETF GBP Hdg Acc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.04% |
SBIO.L Invesco Nasdaq Biotech UCITS ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
SBIO.L and EQGB.L have a correlation of 0.37, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, EQGB.L is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.
EQGB.L is cheaper with a 0.35% expense ratio, compared with 0.40% for SBIO.L.
SBIO.L is categorized as Health & Biotech Equities, while EQGB.L is Nasdaq-100. SBIO.L tracks NASDAQ Biotechnology TR USD, while EQGB.L tracks NASDAQ-100 Index. Their fees differ too: 0.40% for SBIO.L and 0.35% for EQGB.L.
Find the right allocation for SBIO.L and EQGB.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer